14-3-3-zeta mediates GLP-1 receptor agonist action to alter α cell proglucagon processing

Area of Science:

• Endocrinology
• Metabolic Diseases
• Cell Biology

Background:

• Recent studies highlight the role of pancreatic α cells in glucose-stimulated insulin secretion (GSIS).
• Glucagon-like peptide-1 receptor (GLP-1R) agonists are effective in diabetes treatment by potentiating GSIS.
• The intricate paracrine interactions between α and β cells concerning GLP-1R agonist action remain largely undefined.

Purpose of the Study:

• To elucidate the bidirectional paracrine communication between α and β cells in mediating the effects of the GLP-1R agonist, liraglutide.
• To investigate the molecular mechanisms underlying GLP-1R signaling-induced activation of α cell GLP-1 expression.

Main Methods:

• Utilized α cell ablation in male mice to assess the impact on liraglutide's enhancement of GSIS.
• Investigated the role of secreted protein factors in mediating β cell GLP-1R signaling to α cells.
• Examined the regulation of α cell GLP-1 production by the signaling protein 14-3-3-zeta in mouse and human islets.

Main Results:

• Liraglutide's ability to enhance GSIS was significantly blunted following α cell ablation.
• Identified a secreted protein factor mediating the effect of β cell GLP-1R signaling on α cell GLP-1 expression.
• Demonstrated that 14-3-3-zeta regulates this secreted factor, impacting α cell GLP-1 production in both mouse and human islets.

Conclusions:

• α and β cell paracrine interactions are essential for the glucose-lowering effects of GLP-1R agonists like liraglutide.
• The signaling protein 14-3-3-zeta plays a critical role in mediating cross-talk between β and α cells.
• Targeting 14-3-3-zeta presents a potential therapeutic strategy to augment α cell GLP-1 production for improved diabetes management.